About Event
What You Missed at the Inaugural Proteomics Based Drug Discovery Summit
As the proteomics revolution continued to trailblaze the way for small molecule drugs, the Proteomics Based Drug Discovery Summit offered 3 days of jam-packed content. Our delegates addressed their biggest challenges and learned the latest advances proteomics such as:
Optimize your entire workflow with data-led talks on improving sample prep, assay design, data acquisition and analysis to increase experiment uptime and improve the throughput of data production
Learn the latest advances in data independent acquisition, labelling techniques, SETSA and more to complement your mass spectrometry data and gain a deep and holistic profile of your protein of interest
Advance covalent drugs, molecular glues, protein degraders and stabilizers with optimized proteomics as we cover an array of small molecule modalities to drug more undruggable diseases
What You Missed at the World’s First Industry Dedicated Proteomics Summit
Automate and miniaturize your sample preparation to develop high throughput mass spectrometry workflows without losing sensitivity with Plexium, Sanofi & Monte Rosa Therapeutics
Translate your small molecule drugs into the clinic with insights on mechanism of action, protein-protein interactions and protein networks from Covant Therapeutics, Pfizer & Rezo Therapeutics
Advance your screening toolkits to identify more “ligandable residues” for reliable drug discovery with Novartis, Vicinitas Therapeutics & Scorpion Therapeutics
Discover the bleeding edge of covalent drugs, molecular glues and degraders with next-generation platforms by Monte Rosa Therapeutics, BridGene Biosciences & Hyku Biosciences
Uncover selectivity profiles, target engagement, post-translational modifications and structural insights using the latest assays developed by Bayer, Biogen & Relay Therapeutics
Was This the Right Summit for You?
Were you seeking to connect with decision-makers, experts, and key opinion leaders (KOLs) in the proteomics field, including VPs, Directors, and Scientists leading Proteomics, Chemical Biology, and Chemoproteomics teams in biopharma?
This exclusive community united over three days to propel the field forward and explore next-generation proteomics platforms. This gathering of drug developers, small molecule experts, and academic thought leaders offered the perfect opportunity to assess the latest advancements, gain actionable insights to bring back to the team, and unlock the full potential of the proteome.
Companies on the 2025 Program:
We Accessed Never-Before-Seen Data at the World’s First End-to-End
Proteomics Summit
What Your Peers Have to Say:
Ning Deng
Director, IMTAC Discovery
BridGene Bioscience
It’s an excellent opportunity to showcase our unique technology, opening the door to potential collaborations. It’s also a valuable chance for learning and networking.
The field of chemoproteomics/proteomics is rapidly evolving, and I would like to see how different organizations incorporate these improvements to optimize their drug discovery and target validation approaches.
Tyzoon Nomanbhoy
Vice President, Chemical Biology
Vicinitas Therapeutics
The field of chemoproteomics/proteomics is rapidly evolving, and I would like to see how different organizations incorporate these improvements to optimize their drug discovery and target validation approaches.
Tyzoon Nomanbhoy, Vice President, Chemical Biology, Vicinitas Therapeutics
It’s an excellent opportunity to showcase our unique technology, opening the door to potential collaborations. It’s also a valuable chance for learning and networking.
Ning Deng, Director, IMTAC Discovery, BridGene Bioscience